Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators
AssigneeAtraZeneca AB
InventorsMarianne Swanson, Kay Brickmann, Lanna Li
Life of this patent
Estimating the term…
Loading patent…
AssigneeAtraZeneca AB
InventorsMarianne Swanson, Kay Brickmann, Lanna Li
Estimating the term…
The present invention relates to certain novel compounds of formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
A compound of general formula (I)
2-Butyl-4-{[4-(difluoromethoxy)phenyl]amino}-5-phenylisothiazole-3(2H)-thione 1,1-dioxide, or a pharmaceutically acceptable thereof.
20-22. (canceled)
Dependencies are inferred from the claim text.